Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Purchases of Investments

Cash used to buy marketable securities and other investments.

Altimmune, Inc.NASDAQ: ALT

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments grows, but more slowly than its trailing trend

Q1 FY2026 purchases of investments of $43.29M (cash outflow) rose 0.3% year over year, behind the +171.1% change in trailing-twelve-month purchases of investments. Sequentially, it fell 51.1% from the prior quarter. Over 3 fiscal years it compounded at +57.3% a year.

Context

  • Purchases of investments amounted to 696214.6% of revenue in FY2025, up 117559.6 pp from a year earlier.
  • Purchases of investments grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.3% toward the trailing-twelve-month pace of +171.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$43.29M-51.1% QoQ
Last fiscal yearDec 2025
-$285.45M+146.6% YoY
LTMMar 2026
-$285.6M+171.1% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.3%——
1 year+146.6%——
3-year CAGR+57.3%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(285.45M) USD
Year-over-year change
-146.6%

Purchases of Investments vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +171.1% is the 2nd highest of 6, against a peer median of +129.9%.
  • Purchases of investments amounts to 793327.8% of revenue for ALT, versus a peer median of 498.7%.
ALT Competitors
Purchases of Investments for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$1.68B USD+184.5%+64.3%—
VIRVir Biotechnology, Inc.LTM Mar 2026$871.01M USD+2.9%-15.7%1329.9%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$345.19M USD+129.9%+6.9%498.7%
ALTAltimmune, Inc.LTM Mar 2026$285.6M USD+171.1%+57.3%793327.8%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$274.16M USD+157.1%+103.4%385.6%
ABUSArbutus Biopharma CorporationLTM Mar 2026$252.14M USD+67.2%—131.7%
IVAInventiva S.A.FY2025€127.69M EUR—+4935.6%2848.4%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$0 USD———
BMEABiomea Fusion, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ALT) —+129.9%+64.3%498.7%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Depreciation & Amortization551K493K477K238K112K
Deferred Income Tax0000(681K)
Stock-Based Compensation5.52M8.1M10.64M14.39M16.08M
Change in Working Capital(251K)14.11M(8.27M)4.48M6.75M
Accounts Receivables6.53M3.3M(2.31M)1.74M2.06M
Inventory00000
Accounts Payables1.42M2.77M(2.73M)(1.86M)2.51M
Other Working Capital(8.21M)8.04M(3.23M)4.6M2.19M
Other Non-Cash Items13.03M(578K)9.79M(3.9M)(1.7M)
Operating Cash Flow(78.24M)(62.59M)(75.81M)(79.85M)(67.54M)
Capital Expenditures(12.31M)(126K)(47K)0(11K)
Acquisitions (Net)00000
Purchases of Investments(7.59M)(73.27M)(88.63M)(115.73M)(285.45M)
Sales of Investments107.43M0102.41M87.35M152.99M
Other Investing Activities(195K)0000
Investing Cash Flow87.52M(73.4M)13.73M(28.39M)(132.47M)
Debt Repayment000033.92M
Common Stock Issued65.04M56.35M86.6M9.99M173.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities58K434K(496K)50K(709K)
Financing Cash Flow65.1M56.78M86.11M10.04M206.84M
Effect of Forex Changes00000
Net Change in Cash74.38M(79.2M)24.03M(98.19M)6.83M
Free Cash Flow(90.55M)(62.71M)(75.86M)(79.85M)(67.55M)

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.